Colorectal liver metastases are common and should be considered for treatment in a multidisciplinary setting. Surgery is the treatment of choice providing the metastases are resectable. In recent years the benefit of neoadjuvant chemotherapy has been established to downstage metastases and render them amenable to surgical excision. This aspect, as well as the role of adjuvant chemotherapy, is discussed and critically appraised in this article.
no major differences in post-operative complications. A new study is being devised in which cetuximab is added to the chemotherapy regime alone or with bevacizumab. These results are awaited with interest.
Radiofrequency Ablation
There is increasing interest in the role of radiofrequency ablation of liver metastases. Numerous reports have suggested improvements in survival in patients with unresectable disease. Five-year survival rates between 23 and 58% and even 10-year survival rates of up to 25% have been reported. 14, 15 This is a relatively minimally invasive technique associated with a low incidence of toxicity. Radiofrequency ablation can be used to extend the role of surgery by enabling a hemi-hepatectomy to be performed with radiofrequency ablation of lesions in the adjacent lobe carried out either percutaneously or intra-operatively. Other studies have even suggested that patients with resectable disease can be treated with radiofrequency ablation, thus avoiding the problems of major surgery. [16] [17] [18] In the same way that surgery is combined with chemotherapy, so radiofrequency ablation should be combined with appropriate chemotherapy. There is no doubt that such therapy must be discussed in a multidisciplinary meeting, and careful selection is essential to achieve good results.
Conclusion
All otherwise fit patients with CRLMs should be referred to a 
